✦ LIBER ✦

2187 CORRELATING MULTIPARAMETRIC PROSTATE MRI (MP-MRI) SUSPICION FOR PROSTATE CANCER WITH MRI/ULTRASOUND (MR/US) FUSION GUIDED BIOPSY RESULTS AND GLEASON GRADE

✍ Scribed by Rais-Bahrami, Soroush; Siddiqui, M. Minhaj; Stamatakis, Lambros; Vourganti, Srinivas; Hoang, Anthony N.; Walton-Diaz, Annerleim; Logan, Jennifer; Truong, Hong; Nix, Jeffrey; Turkbey, Baris; Choyke, Peter L.; Wood, Bradford J.; Pinto, Peter A.

Book ID: 123025193
Publisher: Lippincott Williams and Wilkins
Year: 2013
Tongue: English
Weight: 168 KB
Volume: 189
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2013.02.2096

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2100 CANCER DETECTION RATES ON MR / ULTR

2100 CANCER DETECTION RATES ON MR / ULTRASOUND (US) FUSED IMAGE GUIDED PROSTATE BIOPSIES DIRECTLY CORRELATES WITH MULTI-PARAMETRIC MRI

✍ Chung, Paul H.; Rastinehad, Ardeshir R.; Baccala, Angelo A.; Kruecker, Jochen; X 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 96 KB

Targeted MRI-guided Prostate Biopsies fo

Targeted MRI-guided Prostate Biopsies for the Detection of Prostate Cancer: Initial Clinical Experience With Real-time 3-Dimensional Transrectal Ultrasound Guidance and Magnetic Resonance/Transrectal Ultrasound Image Fusion

✍ Fiard, Gaelle; Hohn, Noelie; Descotes, Jean-Luc; Rambeaud, Jean-Jacques; Troccaz 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 598 KB

Can multiparametric magnetic resonance i

Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St Peter׳s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.

✍ Abd-Alazeez, Mohamed; Ahmed, Hashim U.; Arya, Manit; Allen, Clare; Dikaios, Niko 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 415 KB